Levi & Korsinsky Alerts PepGen Inc. Investors About Class Action Lawsuit and Key Deadline
On June 17, 2025, legal firm Levi & Korsinsky, LLP issued a crucial alert to investors of PepGen Inc. (NASDAQ: PEPG), notifying them of a class action securities lawsuit. This lawsuit stems from allegations of securities fraud that adversely affected PepGen investors during a specific period from March 7, 2024, to March 3, 2025.
The lawsuit focuses on seeking recovery for investors who experienced losses due to alleged fraudulent behavior by the company's executives. The complaint indicates that investors were misled regarding PepGen's lead product candidate, PGN-EDO51. The defendants are accused of providing false information about the drug's effectiveness and safety, suggesting that it was more reliable than it actually was. The lawsuit claims that critical aspects of the phase two CONNECT2 study were dangerously flawed, questioning its suitability for FDA approval.
The claims highlighted in the filed complaint include:
1. Misrepresentation of PGN-EDO51: The drug was not as effective or safe as suggested by company statements.
2. Concerns Over CONNECT2 Study: The phase two study was allegedly not only dangerous but deficient, compromising its potential for successful FDA approval.
3. Market Overstatement: Due to these misrepresentations, the eventual halt of the CONNECT2 study and overstated clinical and commercial prospects led to significant losses for investors.
Due to these actions, the lawsuit maintains that the public statements from the executives were materially false and misleading during the period in question.
For those who suffered financial losses in PepGen Inc. due to these issues, it is essential to act quickly. Investors have until August 8, 2025, to file a request to serve as lead plaintiffs in the class action. It’s noteworthy that filing for lead plaintiff status is not a prerequisite for being eligible to share in any eventual recovery from this litigation.
One of the most appealing aspects of this class action is that there are no upfront costs associated for class members. Eligible investors can participate without any out-of-pocket expenses, making it a viable option for those affected.
Levi & Korsinsky boasts a robust history of over 20 years in advocating for aggrieved shareholders, securing hundreds of millions for clients in complex securities litigation. With a dedicated team of over 70 professionals, they have established themselves as one of the top firms in the United States for securities class action cases, as evidenced by their consistent recognition in the ISS Securities Class Action Services' Top 50 Report.
Investors wishing to gather more information or to take action can reach out directly to Levi & Korsinsky. Specifically, Joseph E. Levi, Esq. is available at his email ([email protected]) or by telephone at (212) 363-7500. The firm’s main office is located at 33 Whitehall Street, 17th Floor, New York, NY 10004. Investors can also visit their official website for further guidance.
This lawsuit represents an important opportunity for PepGen Inc. investors to potentially secure compensation for losses incurred due to misleading corporate practices. Given the critical timeline, those affected should not hesitate to reach out and explore their options.
Class Action Overview
The lawsuit focuses on seeking recovery for investors who experienced losses due to alleged fraudulent behavior by the company's executives. The complaint indicates that investors were misled regarding PepGen's lead product candidate, PGN-EDO51. The defendants are accused of providing false information about the drug's effectiveness and safety, suggesting that it was more reliable than it actually was. The lawsuit claims that critical aspects of the phase two CONNECT2 study were dangerously flawed, questioning its suitability for FDA approval.
Details of the Allegations
The claims highlighted in the filed complaint include:
1. Misrepresentation of PGN-EDO51: The drug was not as effective or safe as suggested by company statements.
2. Concerns Over CONNECT2 Study: The phase two study was allegedly not only dangerous but deficient, compromising its potential for successful FDA approval.
3. Market Overstatement: Due to these misrepresentations, the eventual halt of the CONNECT2 study and overstated clinical and commercial prospects led to significant losses for investors.
Due to these actions, the lawsuit maintains that the public statements from the executives were materially false and misleading during the period in question.
Next Steps for Investors
For those who suffered financial losses in PepGen Inc. due to these issues, it is essential to act quickly. Investors have until August 8, 2025, to file a request to serve as lead plaintiffs in the class action. It’s noteworthy that filing for lead plaintiff status is not a prerequisite for being eligible to share in any eventual recovery from this litigation.
Participation Costs
One of the most appealing aspects of this class action is that there are no upfront costs associated for class members. Eligible investors can participate without any out-of-pocket expenses, making it a viable option for those affected.
Why Levi & Korsinsky?
Levi & Korsinsky boasts a robust history of over 20 years in advocating for aggrieved shareholders, securing hundreds of millions for clients in complex securities litigation. With a dedicated team of over 70 professionals, they have established themselves as one of the top firms in the United States for securities class action cases, as evidenced by their consistent recognition in the ISS Securities Class Action Services' Top 50 Report.
Contact Information
Investors wishing to gather more information or to take action can reach out directly to Levi & Korsinsky. Specifically, Joseph E. Levi, Esq. is available at his email ([email protected]) or by telephone at (212) 363-7500. The firm’s main office is located at 33 Whitehall Street, 17th Floor, New York, NY 10004. Investors can also visit their official website for further guidance.
This lawsuit represents an important opportunity for PepGen Inc. investors to potentially secure compensation for losses incurred due to misleading corporate practices. Given the critical timeline, those affected should not hesitate to reach out and explore their options.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.